Plasma circulating tumor DNA (ctDNA) enables non-invasive monitoring of metastatic cancer. However, the detection of low tumor content (TC) via tumor tissue-agnostic approaches remains challenging. We introduce METER, a computational strategy exploiting tumor-type specific DNA methylation patterns for sensitive ctDNA detection, accurate quantification, and subtyping from plasma low-pass (0.5-1x) whole-methylome sequencing. In longitudinal samples from metastatic breast cancer patients, METER demonstrated a stronger association with clinical outcomes than both state-of-the-art ctDNA methods and matched circulating tumor cell (CTC) counts, even at TC below 3%. METER (https://github.com/caos-lab-unifi/METER) integrates TC estimation and subtyping in a single framework, enabling sensitive and accurate analyses for precision oncology.
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing / Paoli, Marta; Galardi, Francesca; Nardone, Agostina; Biagioni, Chiara; Romagnoli, Dario; Di Donato, Samantha; Franceschini, Gian Marco; Livraghi, Luca; Pestrin, Marta; Sanna, Giuseppina; Risi, Emanuela; Migliaccio, Ilenia; Moretti, Erica; Malorni, Luca; Biganzoli, Laura; Demichelis, Francesca; Benelli, Matteo. - In: GENOME MEDICINE. - ISSN 1756-994X. - 18:1(2026), pp. 2701-2720. [10.1186/s13073-026-01603-3]
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing
Paoli, MartaCo-primo
;Franceschini, Gian Marco;Demichelis, FrancescaCo-ultimo
;
2026-01-01
Abstract
Plasma circulating tumor DNA (ctDNA) enables non-invasive monitoring of metastatic cancer. However, the detection of low tumor content (TC) via tumor tissue-agnostic approaches remains challenging. We introduce METER, a computational strategy exploiting tumor-type specific DNA methylation patterns for sensitive ctDNA detection, accurate quantification, and subtyping from plasma low-pass (0.5-1x) whole-methylome sequencing. In longitudinal samples from metastatic breast cancer patients, METER demonstrated a stronger association with clinical outcomes than both state-of-the-art ctDNA methods and matched circulating tumor cell (CTC) counts, even at TC below 3%. METER (https://github.com/caos-lab-unifi/METER) integrates TC estimation and subtyping in a single framework, enabling sensitive and accurate analyses for precision oncology.| File | Dimensione | Formato | |
|---|---|---|---|
|
2026_GenomeMed_Paoli_s13073-026-01603-3.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
3.49 MB
Formato
Adobe PDF
|
3.49 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione



